The primary outcome was clinical response at week 8 defined as decrease in total MS of at least 3 points and 30% with decrease in RBS of at least 1 point or absolute RBS of 0 or 1, while secondary outcomes included clinical remission rate at week 8, mucosal healing rate at week 8, and changes from baseline in total MS, partial MS, modified Riley score, and various biomarkers including C-reactive protein, albumin, and calprotectin at multiple timepoints through week 24
SURMOUNT-1 (N=2,539) showed 20.9% mean weight loss at 72 weeks with the 15 mg dose [2]
The primary difference is half-life
By stabilizing blood sugars and limiting insulin resistance, Ozempic can help improve overall metabolic health
Is there more beneath the surface than brand names
For the full safety picture, read our retatrutide side effects overview